Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

MMJ PhytoTech Ltd (ASX:MMJ) AGM Presentation

MMJ PhytoTech
Posted on: 29 Nov 16

Perth, Nov 28, 2016 AEST (ABN Newswire) - MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide the company's AGM Presentation with the topic "Developing a World-Class Pure Play Cannabis Company".

Year In Review - Execution of Key Milestones

- MMJ is the first ASX-listed company to become a Licensed Producer under Marihuana for Medical Purposes Regulations - framework now known as Access to Cannabis for Medical Purposes Regulations ("ACMPR")

- Execution of a binding term sheet with Canadian-based Harvest One Capital Corp. ("Harvest One") (CVE:WON) for the sale to Harvest One of 100% of the issued shares of UG and Satipharm

- Import Permit received enabling importation of 1kg of cannabis seeds, which paves the way for commencement of cultivation at Duncan Facility in December 2016

- United Greeneries executed a binding letter of intent ("LOI") with Cowichan Tribes in respect to the leasing of a 13-acre strategic land package ("Expansion Land") located immediately adjacent to the Company's existing Duncan Facility

- Positioned company for entry into evolving Australian market with signing of strategic partnerships with Australian dispensary, Fresh Therapeutics Compounding Pharmacy, and Epilepsy Action Australia

- Strengthening of pharmaceutical experience with appointment of Stanislav Sologubov as CEO of Satipham AG and Catherine Harvey as Chief Operating Officer of MMJ

- Israel subsidiary, PhytoTech Therapeutics (PTL), successfully completed Phase 1 Clinical Trial highlighting the safety and performance of Gelpell-CBD capsules

- PTL Phase 2 Clinical Trial into treatment of pediatric epilepsy to commence imminently

TSX- V Transaction Summary

MMJ shareholders will have significant exposure to two of the largest commercial opportunities in the global cannabis sector.

- MMJ PhytoTech ('MMJ' or the 'Company') to list Canadian subsidiary United Greeneries ('UG') together with Swiss subsidiary Satipharm ('SAT') on the TSX Venture Exchange ('TSX-V') (the "Transaction").

- MMJ has executed a binding term sheet with Canadian-based Harvest One Capital Corp. ("Harvest One") (CVE:WON) for the sale to Harvest One of 100% of the issued shares of UG and Satipharm

- Harvest One proposal includes total consideration for UG assets of C$42M - $40M equity (53.3M shares @ $0.75/share) and $2M cash

- Pro Forma ownership of TSX listed entity approx. 70%

- The proposed TSX-V listing is designed to allow for greater direct market value comparisons between MMJ's world-class cannabis assets and existing TSX-V listed cannabis producers

- Robust appetite for cannabis-focused equities - circa C$200M raised by MMJ's Canadian peers since March 2016

- MMJ expects the transaction to be finalised and the resulting issuer to be traded on the TSX-V in Q1 2017

The Year Ahead - 2017

- MMJ views the emerging Canadian recreational market as a significant near-term growth catalyst and as such is committed to capturing a strategic first-mover advantage as market is legalized in 2017

- Finalization of TSX-V RTO transaction and subsequent roll out of Canadian marketing strategy

- Commencement of cannabis cultivation in December 2016 with a view to rolling out aggressive expansion plan throughout 2017

- Duncan Facility cultivation to include simultaneous growing of multiple unique cannabis strains that previously have not been available to Canadian consumers

- Drive revenue and sales growth of the Company's exclusive Gelpell Capsules throughout key regulated markets in Europe

- Remains committed to successful execution of Phase 2 Clinical Trial in Israel

To view the presentation, please visit:

Editor's Details

Mike Wood

Last updated on: 29/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.